paclitaxel has been researched along with pi103 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayakawa, M; Kaizawa, H; Kawaguchi, K; Koizumi, T; Ohishi, T; Ohta, M; Okada, M; Parker, P; Raynaud, FI; Tsukamoto, S; Waterfield, MD; Workman, P; Yamano, M | 1 |
| Chen, Y; Han, J; Liu, T; Song, Y; Wang, M; Xu, H; Yang, C; Zhang, L; Zheng, C; Zhu, J | 1 |
| Dilasser, F; Dubreuil, D; Le Gall, E; Le Guével, R; Lebreton, J; Léonel, E; Loirand, G; Martens, T; Pipelier, M; Rousselle, M; Sauzeau, V; Sengmany, S; Sitter, M | 1 |
| Gu, D; Hu, Y; Ma, X; Sheng, R; Wang, C; Wei, J | 1 |
| Hou, Y; Kuang, W; Min, W; Sun, C; Wang, L; Wang, X; Wang, Y; Xia, F; Yang, P; Yuan, K; Zhang, F; Zhang, H; Zhu, Y | 1 |
5 other study(ies) available for paclitaxel and pi103
| Article | Year |
|---|---|
Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Humans; Hydrazones; Imidazoles; Inhibitory Concentration 50; Isoenzymes; Mice; Molecular Structure; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Subunits; Pyridines; Structure-Activity Relationship; Sulfur; Temperature; Xenograft Model Antitumor Assays | 2007 |
Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor.
Topics: Administration, Oral; Amino Acid Sequence; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Enzyme Inhibitors; Humans; Male; Models, Molecular; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Conformation; Rats; Signal Transduction; Structure-Activity Relationship; Sulfonamides; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Synthesis and biological evaluation of 3-amino-, 3-alkoxy- and 3-aryloxy-6-(hetero)arylpyridazines as potent antitumor agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Pyridazines | 2019 |
Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies.
Topics: Administration, Oral; Animals; Antineoplastic Agents; B-Lymphocytes; Benzothiadiazines; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Design; Lymphoma, B-Cell; Molecular Docking Simulation; Protein Kinase Inhibitors; Rats, Sprague-Dawley | 2019 |
Discovery of Novel Phosphoinositide-3-Kinase α Inhibitors with High Selectivity, Excellent Bioavailability, and Long-Acting Efficacy for Gastric Cancer.
Topics: Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Cell Proliferation; Humans; Phosphatidylinositol 3-Kinases; Phosphatidylinositols; Phosphoinositide-3 Kinase Inhibitors; Stomach Neoplasms; Structure-Activity Relationship | 2022 |